FDA-approved drugs to combat inflammation and metabolic dysfunction in macular degenerationsView Session View Presentation
Add to Schedule Print Abstract
Abstract Number: 4215
AuthorBlock: Aparna Lakkaraju1
1School of Medicine, University of California, San Francisco, San Francisco, California, United States;
DisclosureBlock: Aparna Lakkaraju, None;
Damage to the retinal pigment epithelium (RPE) is an initiating factor that eventually culminates in vision loss in macular degenerations. Therefore, drugs that preserve RPE health and function could halt AMD at its earliest stages. We have recently identified ceramide as a novel drug target in AMD because it regulates complement activity, metabolic dysfunction and inflammation, three pathways implicated in AMD pathogenesis. This presentation will discuss our recent studies showing that clinically approved drugs that decrease RPE ceramide correct multiple dysfunctional pathways implicated in early AMD.